Want news about Sun Pharmaceutical Industries to land in your mailbox?


Sun Pharma launches generic Ethyol
Sun Pharmaceutical Industries Ltd. announced today that it has commercially launched generic Amifostine for injection 500mg, which is therapeutically equivalent to MedImmune’s Ethyol®. Sun Pharma’s product is being sold in the United States by its marketing partner Caraco Pharmaceutical Laboratories. Sun Pharma had received a USFDA approval for this earlier in Mar 2008. Ethyol® has annual sales of approximately USD 80 million in the US.
Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, has a 180-day marketing exclusivity.
Ethyol® is covered under 3 patents - ‘471 (July 31, 2012), ‘731 (July 31, 2012) and ‘409 (Dec 8, 2017). This ANDA was filed with para IV certification against all the patents. Medimmune filed a suit in the District Court of Maryland and the case is under litigation.
Sourced From: Sun Pharmaceutical Industries Ltd
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
MS Banga
President - Global Foods, Home, and Personal Care Business
Unilever
Right time to move on, Unilever healthy again: Vindi Banga
VVS Murthy
CFO
Dishman Pharma
Dishman Pharma invests $20m in new API facility
T Srinivasa Rao
VP-Finance
Rain Commodities
See better op margins, volumes in CY10: Rain Commodities
Rahul Shah
Executive Director
Nitin Fire Protection
See 20-25% revenue growth in FY11: Nitin Fire Protection
-
Most Read
-
Most Viewed
- Don't rule out double dip recession in West: Chrys Capital

- Sudarshan Sukhani's top 5 picks for trade today

- Ashwani Gujral's top five picks for today's trade

- See good response to Persistent Systems IPO: Udayan

- Gold ETFs: Best way to invest in the precious metal?

- See better performance from RIL in Q4 vs Q3: Kotak Inst Eq

- Why is First Global negative on metal, oil sector?

- Shilpa Shetty's stake in Rajasthan Royals under I-T scanner

- RIL is unlikely to report USD 9/bbl GRM in Q4: SP Tulsian

- Apply for Persistent IPO, target of Rs 350: Swastika
- Shree Ganesh plans to raise Rs 375 cr via IPO
Source: Business Line
- India`s sovereign wealth fund
Source: ft.com
- London`s miners lifted by global growth hopes
Source: ft.com
- Hero Honda may set up 4th plant in Himachal Pradesh
Source: Business Line

















